Literature DB >> 33175198

Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.

P Zappasodi1, M Brociner2, G Merati2, M E Nizzoli2, E Roncoroni3, E Boveri4, C Castagnola3, L Arcaini3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33175198     DOI： 10.1007/s00277-020-04333-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  1 in total

1.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265
  1 in total
  1 in total

Review 1.  Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

Authors:  Serena Brancati; Lucia Gozzo; Giovanni Luca Romano; Calogero Vetro; Ilaria Dulcamare; Cinzia Maugeri; Marina Parisi; Laura Longo; Daniela Cristina Vitale; Francesco Di Raimondo; Filippo Drago
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.